Crohn’s Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulator, Other), By Application (Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 12.04 Billion
CAGR (2026-2031)	4.09%
Fastest Growing Segment	Online pharmacies
Largest Market	North America
Market Size (2031)	USD 15.31 Billion

Market Overview

The Global Crohn’s Disease Treatment Market will grow from USD 12.04 Billion in 2025 to USD 15.31 Billion by 2031 at a 4.09% CAGR. The Global Crohn’s Disease Treatment Market encompasses pharmaceutical interventions including immunomodulators, antibiotics, and biologic therapies designed to induce and maintain remission in patients with this chronic inflammatory condition. Growth is propelled by the rising disease prevalence across industrialized nations and the continued approval of novel therapeutic agents. According to the Crohn's & Colitis Foundation, in 2024, an estimated 100,429 American youth under the age of 20 were living with Inflammatory Bowel Disease, with Crohn's disease prevalence notably surpassing ulcerative colitis in this demographic. This data underscores the expanding patient pool necessitating ongoing medical management.

However, the market faces a significant impediment regarding the high cost associated with advanced biologic therapies, which often creates barriers to patient access and reimbursement. Stringent regulatory requirements and the substantial financial burden of continuous treatment plans can delay the adoption of effective medications, particularly in regions with limited healthcare budgets. Consequently, these economic pressures may restrict the market penetration of premium therapeutic options and compel healthcare providers to rely on older and less expensive alternatives.

Key Market Drivers

The relentlessly increasing global prevalence and incidence of Crohn’s disease acts as the primary engine for market expansion. This growing disease burden is no longer confined to Western nations but is visibly accelerating in newly industrializing regions due to shifting environmental factors and lifestyle changes. The expansion of the patient pool necessitates long-term, continuous medical management, thereby guaranteeing sustained demand for therapeutic interventions. According to the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA), May 2025, in the 'World IBD Day Report 2025', there are currently over 10 million people worldwide living with inflammatory bowel diseases, a statistic that underscores the immense scale of the addressable patient population requiring effective treatment.

Simultaneously, the market is being reshaped by the rapid adoption of advanced biologics and the approval of novel drug classes which offer superior efficacy and safety profiles compared to legacy therapies. Healthcare providers are increasingly transitioning patients to next-generation mechanisms, such as interleukin inhibitors, to achieve deeper remission, driving significant revenue growth for innovative formulations. This trend is substantiated by financial data; according to AbbVie, January 2025, in the 'Fourth-Quarter and Full-Year 2024 Financial Results', global net revenues for the advanced therapy Skyrizi reached $11.7 billion for the full year 2024. Conversely, according to Johnson & Johnson, in 2025, the established biologic Stelara generated $10.4 billion in sales during 2024, illustrating the massive scale of investment in biologic care despite the mounting pressure from newer entrants and biosimilars.

Download Free Sample Report

Key Market Challenges

The high cost of advanced biologic therapies constitutes a substantial barrier impeding the expansion of the Global Crohn’s Disease Treatment Market. While these drugs offer efficacy, their pricing structures create severe accessibility issues for patients and strain healthcare budgets. Insurance providers frequently implement strict reimbursement protocols, such as step therapy, compelling patients to fail on cheaper alternatives before approving premium treatments. This financial toxicity discourages adherence and delays the initiation of optimal care, directly reducing the revenue potential for advanced therapeutic agents.

The economic strain on the patient population is quantifiable and severe. According to the Crohn's & Colitis Foundation, in 2024, more than 40% of inflammatory bowel disease patients made significant financial sacrifices to afford their healthcare. Furthermore, 63% of patients prescribed medication reported facing specific financial barriers that prevented them from obtaining their treatment. This inability to afford prescribed regimens limits the market penetration of high-value biologics and forces a market reliance on lower-cost generics or biosimilars.

Key Market Trends

The Accelerating Adoption of Cost-Effective Biosimilars is fundamentally restructuring the Global Crohn’s Disease Treatment Market by introducing affordable alternatives to high-priced legacy biologics. As patent exclusivities for major monoclonal antibodies expire, regulatory bodies are expediting the approval of biosimilar candidates, which mitigates the financial barriers currently restricting patient access to biologic therapy. This influx of lower-cost options is compelling payers to adjust formulary structures, thereby driving market penetration in cost-sensitive regions and challenging the dominance of originator drugs. According to AscellaHealth, January 2025, in the 'FDA Approved 18 New Biosimilars This Year' report, the FDA approved six distinct biosimilars for the blockbuster drug Stelara in 2024 alone, signaling a massive shift in prescription volume toward these economical therapeutic options.

Concurrently, the Shift Toward Oral Small Molecule Therapeutics is redefining treatment paradigms by offering potent efficacy combined with the convenience of pill-based administration. Unlike traditional biologics that require subcutaneous or intravenous delivery, advanced Janus kinase (JAK) inhibitors and S1P receptor modulators provide patients with a non-invasive option that significantly improves lifestyle flexibility and adherence. This transition is rapidly gaining momentum as clinical data demonstrates that these oral therapies can achieve remission rates comparable to injectable biologics. According to AbbVie, January 2025, in the 'Fourth-Quarter and Full-Year 2024 Financial Results', global net revenues for the oral JAK inhibitor Rinvoq reached $6.0 billion for the full year 2024, reflecting the robust and growing demand for convenient, advanced therapeutic mechanisms.

Segmental Insights

The online pharmacies segment is recognized as the fastest-growing distribution channel in the global Crohn’s disease treatment market, primarily due to the rising preference for convenient access to long-term medications. Since Crohn's disease requires consistent management, patients increasingly rely on digital platforms that provide home delivery and automated refill options. The growth is further accelerated by the widespread adoption of e-commerce and the availability of cost-effective pricing models. Additionally, strict adherence to safety protocols by digital vendors enhances patient confidence, ensuring secure and reliable access to necessary therapeutic prescriptions.

Regional Insights

North America leads the Global Crohn’s Disease Treatment Market, primarily driven by the high prevalence of inflammatory bowel conditions across the United States and Canada. This regional dominance is reinforced by a well-established healthcare infrastructure and comprehensive reimbursement frameworks that facilitate patient access to essential medications. The U.S. Food and Drug Administration plays a pivotal role by actively approving new biologic therapies, ensuring rapid market entry for current treatments. Furthermore, the concentrated presence of major pharmaceutical companies fosters continuous research and development, solidifying the region's position as the top revenue contributor globally.

Recent Developments

• In March 2025, Johnson & Johnson obtained approval from the U.S. Food and Drug Administration for Tremfya (guselkumab) to treat adults with moderately to severely active Crohn's disease. This authorization established the medication as the first interleukin-23 inhibitor to offer both subcutaneous and intravenous induction regimens for this condition. The regulatory clearance was supported by data from the Phase 3 GALAXI and GRAVITI clinical trials, which demonstrated the efficacy of the drug in achieving endoscopic response and clinical remission. This development allowed the company to broaden its immunology portfolio and provide a flexible therapeutic option for patients.
• In January 2025, Eli Lilly and Company received approval from the U.S. Food and Drug Administration for Omvoh (mirikizumab-mrkz) for the treatment of adults with moderately to severely active Crohn's disease. This development marked the expansion of the company's interleukin-23p19 antagonist into a second major inflammatory bowel disease indication, following its earlier authorization for ulcerative colitis. The regulatory decision was based on data from the Phase 3 VIVID-1 study, which showed that the treatment achieved statistically significant improvements in clinical remission and endoscopic response compared to placebo, reinforcing the company's position in the Global Crohn’s Disease Treatment Market.
• In April 2024, Takeda announced that the U.S. Food and Drug Administration approved the subcutaneous administration of Entyvio (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn's disease. This regulatory milestone allowed the company to expand the label for its gut-selective biologic, which was previously available for this indication only via intravenous infusion. The approval was supported by results from the Phase 3 VISIBLE 2 clinical trial, which demonstrated that a statistically significant proportion of patients treated with the subcutaneous formulation achieved long-term clinical remission at week 52 compared to those receiving a placebo.
• In March 2024, Celltrion USA launched Zymfentra (infliximab-dyyb), a subcutaneous formulation of infliximab, for the treatment of adult patients with moderately to severely active Crohn's disease and ulcerative colitis. This product introduction followed approval by the U.S. Food and Drug Administration as the first subcutaneous infliximab option available for maintenance therapy in this therapeutic class. The launch provided a new administration route for a well-established biologic, offering patients the convenience of self-administration at home following an initial intravenous induction. The company supported the commercial availability with patient assistance programs designed to facilitate access to the medication within the Global Crohn’s Disease Treatment Market.

Key Market Players

• Eli Lilly and Company
• AbbVie Inc.
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Celgene Corporation
• Novartis AG
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Mylan N.V.
• Amgen Inc

By Drug Type	By Application	By Distribution Channel	By Region
Antibiotics Amino Salicylates Corticosteroids Immunomodulator Other	Neuropathic Pain Fibromyalgia Chronic Back Pain Arthritic Pain Migraine Post-Operative Pain Cancer Pain Other	Hospital Pharmacies Retail Pharmacies Online Pharmacies	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Crohn’s Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Crohn’s Disease Treatment Market, By Drug Type:

• Antibiotics
• Amino Salicylates
• Corticosteroids
• Immunomodulator
• Other

• Crohn’s Disease Treatment Market, By Application:

• Neuropathic Pain
• Fibromyalgia
• Chronic Back Pain
• Arthritic Pain
• Migraine Post-Operative Pain
• Cancer Pain
• Other

• Crohn’s Disease Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

• Crohn’s Disease Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE